Biovista

Quantum-Si Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Retrieved on: 
Monday, March 6, 2023

Selling, general and administrative expenses were $11.2 million in the fourth quarter of 2022, compared to $13.4 million in the fourth quarter of 2021.

Key Points: 
  • Selling, general and administrative expenses were $11.2 million in the fourth quarter of 2022, compared to $13.4 million in the fourth quarter of 2021.
  • Net loss was $33.1 million in the fourth quarter of 2022, compared to a net loss of $29.4 million in the fourth quarter of 2021.
  • Adjusted EBITDA was negative $24.5 million in the fourth quarter of 2022, compared to negative $20.4 million in the fourth quarter of 2021.
  • Quantum-Si will host a conference call to discuss its fourth quarter and fiscal year 2022 financial results on Monday, March 6, 2023, at 8:30 AM Eastern Time (ET).

Quantum-Si and Biovista Partner to Provide AI-Driven Deep Proteomics Insights from the Platinum™ Next-Generation Protein Sequence Platform Output

Retrieved on: 
Monday, January 9, 2023

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it entered into a partnership and license agreement with Biovista to provide customers greater proteomic insights beyond their protein sequence output.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it entered into a partnership and license agreement with Biovista to provide customers greater proteomic insights beyond their protein sequence output.
  • Biovista leverages AI in multiple formats to analyze massive data repositories and visualize non-obvious networks and associations between proteins, diseases, and drug mechanisms-of-action.
  • "Quantum-Si is leading the next generation of real-world meaningful sequencing," said Dr. Aris Persidis, Biovista’s Co-Founder and President.
  • "We are excited to see deep sequencing and insight generation now available in one integrated platform,” he continued.

Quantum-Si Begins Commercial Shipments of the PlatinumTM Protein Sequencing System and Provides Business Updates at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 9, 2023

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that management will discuss the following business updates at the 41st Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that management will discuss the following business updates at the 41st Annual J.P. Morgan Healthcare Conference.
  • Quantum-Si has begun commercial shipments of the Platinum protein sequencing system.
  • The Company announced a partnership with Aviva Systems Biology, a leading provider of antibody, protein, and immunoassay reagent products, to co-develop sample preparation kits for protein sequencing research workflows with Platinum.
  • The Company reaffirms commitment to fiscal discipline and seeks to extend cash runway beyond the current guidance of 2024.

Global Central Nervous System Diseases Drug Delivery Technologies, Markets & Companies Report 2020 with Profiles of 76 Companies, Their Technologies and 100+ Collaborations

Retrieved on: 
Wednesday, September 23, 2020

DUBLIN, Sept. 23, 2020 /PRNewswire/ -- The "Drug Delivery in Central Nervous System Diseases - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 23, 2020 /PRNewswire/ -- The "Drug Delivery in Central Nervous System Diseases - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • The market for CNS drug delivery technologies is directly linked to the CNS drug market.
  • Profiles of 76 companies involved in drug delivery for CNS disorders are presented along with their technologies, products and 101 collaborations.
  • These include pharmaceutical companies that develop CNS drugs and biotechnology companies that provide technologies for drug delivery.

Artificial Intelligence firm Biovista repositions four promising therapeutics against COVID-19

Retrieved on: 
Wednesday, April 22, 2020

The first drug has the potential to reduce viral replication, limit inflammatory events, and help protect against acute lung injury.

Key Points: 
  • The first drug has the potential to reduce viral replication, limit inflammatory events, and help protect against acute lung injury.
  • The two over-the-counter compounds would be adjunct treatments.These findings are presented in a White Paper which Biovista is making available upon request via email: [email protected] .
  • With a predictive success rate of over 77%, Biovista has significant experience in drug repositioning, on which many of the world's hopes for COVID therapeutics revolve today.
  • Finding existing drugs to target a disease of interest, as in this case with COVID-19
    View original content to download multimedia: http://www.prnewswire.com/news-releases/artificial-intelligence-firm-bio...

Drug Delivery in Central Nervous System (CNS) Diseases - Global Markets to 2028 Featuring 75 Company Profiles & 101 Collaborations

Retrieved on: 
Tuesday, September 17, 2019

Dublin, Sept. 17, 2019 (GLOBE NEWSWIRE) -- The "Drug Delivery in Central Nervous System Diseases - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Dublin, Sept. 17, 2019 (GLOBE NEWSWIRE) -- The "Drug Delivery in Central Nervous System Diseases - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders.
  • Advances in understanding of the cell biology of the BBB have opened new avenues and possibilities for improved drug delivery to the CNS.
  • Profiles of 75 companies involved in drug delivery for CNS disorders are presented along with their technologies, products and 101 collaborations.